Clinical features and outcomes of patients with myasthenia gravis admitted to an intensive care unit: A 20-year retrospective study
Article Sidebar
Main Article Content
Abstract
Background. There are limited data on the clinical characteristics and outcomes of patients with myasthenia gravis (MG) admitted to the intensive care unit (ICU) at Charlotte Maxeke Johannesburg Academic Hospital (CMJAH).
Objectives. The aim was to study the clinical characteristics and outcomes of patients with MG admitted to the CMJAH over two decades.
Methods. A retrospective study was undertaken of patients with MG admitted to the multidisciplinary ICU of CMJAH over a 20-year period, from 1998 to 2017. Demographic data, clinical features, management and outcomes of patients were assessed and reviewed from the case records.
Results. Thirty-four patients with MG were admitted to the ICU during this period: 24 female and 10 male. The mean age ± SD was 37.4 ± 13.0 years, with a range of 16 - 66 years. Four patients were human immunodeficiency virus (HIV)-positive. The mean length of stay (LOS) in ICU was 10.6 ± 20.1 days, ranging from 1 to 115 days. Two patients were diagnosed with MG in the ICU after failure to wean from the ventilator. Overall, 22 patients were intubated and ventilated on admission. Morbidities included self-extubation, aspiration pneumonia and iatrogenic pneumothorax. History of thymectomy was present in 12 patients. The treatments received for MG included pyridostigmine (73.5%), corticosteroids (55.9%), azathioprine (35.3%), plasmapheresis (26.5%) and intravenous immunoglobulin (8.8%). The overall mortality in the ICU was 5.9%.
Conclusion. MG is a serious disorder with considerable morbidity and mortality. It is, however, a potentially manageable disease, provided that appropriate ICU resources are available.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The SAJCC is published under an Attribution-Non Commercial International Creative Commons Attribution (CC-BY-NC 4.0) License. Under this license, authors agree to make articles available to users, without permission or fees, for any lawful, non-commercial purpose. Users may read, copy, or re-use published content as long as the author and original place of publication are properly cited.
Exceptions to this license model is allowed for UKRI and research funded by organisations requiring that research be published open-access without embargo, under a CC-BY licence. As per the journals archiving policy, authors are permitted to self-archive the author-accepted manuscript (AAM) in a repository.
How to Cite
References
Gilhus NE. Myasthenia Gravis. N Engl J Med 2016;375(26):2570-2581. https://doi.org/10.1056/ NEJMra1602678
Alshekhlee A, Miles JD, Katirji B, Preston DC, Kaminski HJ. Incidence and mortality rates of myasthenia gravis and myasthenic crisis in US hospitals. Neurology 2009;72(18):1548-1554. https:// doi.org/10.1212/WNL.0b013e3181a41211
JuelVC.Myastheniagravis:Managementofmyastheniccrisisandperioperativecare.SeminNeurol 2004;24(1):75-81. https://doi.org/10.1055/s-2004-829595
Ling C-S, Shen M-L, Wang Y, et al. The associations of HLA-DRB1 gene polymorphisms with late- onset myasthenia gravis: A meta-analysis. Neurol Sci 2020;41(5):1041-1049. https://doi.org/10.1007/ s10072-019-04213-7
Usman U, Chrisman C, Houston D, Haws CC, Wang A, Muley S. The use of eculizumab in ventilator-dependent myasthenia gravis patients. Muscle Nerve 2021;64(2):212-215. https://doi. org/10.1002/mus.27326
Huan X, Zhao R, Song J, et al. Increased serum IL-2, IL-4, IL-5 and IL-12p70 levels in AChR subtype generalized myasthenia gravis. BMC Immunol 2022;23(1):26. https://doi.org/10.1186/ s12865-022-00501-8
Boldingh MI, Dekker L, Maniaol AH, et al. An up-date on health-related quality of life in myasthenia gravis - results from population based cohorts. Health Qual Life Outcomes 2015;13:115. https://doi.org/10.1186/s12955-015-0298-1
BedlackRS,SandersDB.Ontheconceptofmyastheniccrisis.JClinNeuromusculDis2002;4(1):40- 42. https://doi.org/10.1097/00131402-200209000-00009
Neumann B, Angstwurm K, Mergenthaler P, et al. Myasthenic crisis demanding mechanical ventilation: A multicenter analysis of 250 cases. Neurology 2020;94(3):e299-e313. https://doi. org/10.1212/WNL.0000000000008688
ThomasCE,MayerSA,GungorY,etal.Myastheniccrisis:clinicalfeatures,mortality,complications, and risk factors for prolonged intubation. Neurology 1997;48(5):1253-1260. https://doi.org/10.1212/ wnl.48.5.1253
Spillane J, Hirsch NP, Kullmann DM, Taylor C, Howard RS. Myasthenia gravis--treatment of acute severe exacerbations in the intensive care unit results in a favourable long-term prognosis. Eur J Neurol 2014;21(1):171-173. https://doi.org/10.1111/ene.12115
Ramos-Fransi A, Rojas-García R, Segovia S, et al. Myasthenia gravis: Descriptive analysis of life- threatening events in a recent nationwide registry. Eur J Neurol 2015;22(7):1056-1061. https://doi. org/10.1111/ene.12703
O’Riordan JI, Miller DH, Mottershead JP, Hirsch NP, Howard RS. The management and outcome of patients with myasthenia gravis treated acutely in a neurological intensive care unit. Eur J Neurol 1998;5(2):137-142. https://doi.org/10.1046/j.1468-1331.1998.520137.x
KalitaJ,KohatAK,MisraUK.Predictorsofoutcomeofmyastheniccrisis.NeurolSci2014;35(7):1109- 1114. https://doi.org/10.1007/s10072-014-1659-y
Werneck LC, Scola RH, Germiniani FMB, Comerlato EA, Cunha FMB. Myasthenic crisis: Report of 24 cases. Arq Neuropsiquiatr 2002;60(3-A):519-526. https://doi.org/10.1590/s0004- 282x2002000400001
Damian MS, Ben-Shlomo Y, Howard R, et al. The effect of secular trends and specialist neurocritical care on mortality for patients with intracerebral haemorrhage, myasthenia gravis and Guillain-Barré syndrome admitted to critical care : An analysis of the Intensive Care National Audit & Research Centre (ICNARC) national United Kingdom database. Intensive Care Med 2013;39(8):1405-1412. https://doi.org/10.1007/s00134-013-2960-6
Berrouschot J, Baumann I, Kalischewski P, Sterker M, Schneider D. Therapy of myasthenic crisis. Crit Care Med 1997;25(7):1228-1235. https://doi.org/10.1097/00003246-199707000-00027
Murthy JMK, Meena AK, Chowdary GVS, Naryanan JT. Myasthenic crisis: Clinical features, complications and mortality. Neurol India 2005;53(1):37-40; discussion 40. https://doi. org/10.4103/0028-3886.15050
LiuC,WangQ,QiuZ,etal.Analysisofmortalityandrelatedfactorsin2195adultmyastheniagravis patients in a 10-year follow-up study. Neurol India 2017;65(3):518-524. https://doi.org/10.4103/ neuroindia.NI_804_16
Gilhus NE, Owe JF, Hoff JM, Romi F, Skeie GO, Aarli JA. Myasthenia gravis: A review of available treatment approaches. Autoimmune Dis 2011;2011:847393. https://doi.org/10.4061/2011/847393 21. Onyekwulu FA, Onwuekwe IO. Critical care of myasthenia gravis in a resource poor setting:
A study of South East Nigeria. Neurologist 2010;16(6):368-370. https://doi.org/10.1097/
NRL.0b013e3181c29f25
OssermanKE,GenkinsG.Studiesinmyastheniagravis:Reviewofatwenty-yearexperienceinover 1200 patients. Mt Sinai J Med 1971;38(6):497-537.
Al-Bassam W, Kubicki M, Bailey M, et al. Characteristics, incidence, and outcome of patients admitted to the intensive care unit with myasthenia gravis. J Crit Care 2018;45:90-94. https://doi. org/10.1016/j.jcrc.2018.01.003
Misra UK, Kumar S, Singh VK, Dubey D, Kalita J. Noninvasive ventilation in myasthenia gravis. Neurol India 2020;68(3):648-651. https://doi.org/10.4103/0028-3886.289001
Carr AS, Cardwell CR, McCarron PO, McConville J. A systematic review of population based epidemiological studies in myasthenia gravis. BMC Neurol 2010;10:46. https://doi.org/10.1186/1471- 2377-10-46
Mombaur B, Lesosky MR, Liebenberg L, Vreede H, Heckmann JM. Incidence of acetylcholine receptor-antibody-positive myasthenia gravis in South Africa. Muscle Nerve 2015;51(4):533-537. https://doi.org/10.1002/mus.24348
Al-Bassam W, Kubicki M, Bailey M, et al. Characteristics, incidence, and outcome of patients admitted to the intensive care unit with myasthenia gravis. J Crit Care 2018;45:90-94. https://doi. org/10.1016/j.jcrc.2018.01.003
Paul E, Bailey M, Pilcher D. Risk prediction of hospital mortality for adult patients admitted to Australian and New Zealand intensive care units: Development and validation of the Australian and New Zealand Risk of Death model. J Crit Care 2013;28(6):935-941. https://doi.org/10.1016/j. jcrc.2013.07.058
Berrih-Aknin S, Le Panse R. Myasthenia gravis: A comprehensive review of immune dysregulation and etiological mechanisms. J Autoimmun 2014;52:90-100. https://doi.org/10.1016/j. jaut.2013.12.011
Spillane J, Higham E, Kullmann DM. Myasthenia gravis. BMJ 2012;345:e8497. https://doi. org/10.1136/bmj.e8497
Lascano AM, Lalive PH. Update in immunosuppressive therapy of myasthenia gravis. Autoimmun Rev 2021;20(1):102712. https://doi.org/10.1016/j.autrev.2020.102712
Maddison P, McConville J, Farrugia ME, et al. The use of rituximab in myasthenia gravis and Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry 2011;82(6):671-673. https:// doi.org/10.1136/jnnp.2009.197632
Barth D, Nabavi Nouri M, Ng E, Nwe P, Bril V. Comparison of IVIg and PLEX in patients with myasthenia gravis. Neurology 2011;76(23):2017-2023. https://doi.org/10.1212/ WNL.0b013e31821e5505